Physician profile
Deanyl Denlinger
NPI 1427380427
$1,482.79
in general payments reported to CMS, 2019-2025
29 companies · $1,062 in 2025
The $1,062 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.99 · 2022: $52.77 · 2023: $131 · 2024: $207 · 2025: $1,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,300 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,300.08 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $219.10 | 2021-2025 | Airsupra, Breztri, Tezspire |
| Novo Nordisk INC | $175.91 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $143.85 | 2023-2024 | Veozah |
| Alpha Cognition USA, INC. | $139.70 | 2025 | Zunveyl |
| Abbott Laboratories | $89.45 | 2022-2025 | Freestyle Libre 3 |
| Abbvie INC. | $82.14 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.24 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $52.47 | 2025 | Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $41.23 | 2025 | Spravato, Invega Trinza, Invega Sustenna |
| Xeris Pharmaceuticals, INC. | $39.96 | 2024 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.06 | 2025 | Xifaxan |
| Lilly USA, LLC | $38.46 | 2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.88 | 2025 | Jardiance |
| Merck Sharp & Dohme LLC | $36.01 | 2025 | Gardasil 9, Capvaxive |
| Amgen INC. | $32.08 | 2025 | Repatha, Otezla |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $31.18 | 2025 | The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $28.49 | 2025 | Trelegy Ellipta, Arexvy |
| Aimmune Therapeutics, INC. | $27.71 | 2025 | Vowst |
| Ucb, INC. | $19.78 | 2025 | Nayzilam |
| Currax Pharmaceuticals LLC | $17.68 | 2024 | Contrave |
| Lundbeck LLC | $17.33 | 2025 | Rexulti |
| Amarin Pharma, INC. | $16.66 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.14 | 2025 | |
| Sumitomo Pharma America, INC. | $15.64 | 2025 | Gemtesa |
| Pfizer INC. | $15.25 | 2025 | |
| Alkermes, INC. | $14.44 | 2025 | Aristada, Lybalvi |
| Jazz Pharmaceuticals INC. | $13.83 | 2025 | |
| Boston Scientific Corporation | $13.58 | 2025 | Wavewriter Alpha Prime 16 |
| Vanda Pharmaceuticals INC. | $13.54 | 2025 | Fanapt, Hetlioz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deanyl Denlinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.